← Back to Clinical Trials
Recruiting Phase 2 NCT05357040

Antidepressant Effects of Nitrous Oxide

Trial Parameters

Condition Major Depressive Disorder
Sponsor University of Chicago
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 172
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-06-30
Completion 2026-10-01
Interventions
Nitrous oxide gas for inhalationPlacebo

Brief Summary

To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.

Eligibility Criteria

Inclusion Criteria: 1. Adult (≥18 years, both sexes) 2. DSM-5 criteria for MDD without psychosis, as determined using a structured clinical interview \[Mini International Neuropsychiatric Interview\], MDD, defined by a pre-treatment score \>16 on the HDRS-21 scale and meeting DSM-5 for MDD Exclusion Criteria: 1. A current or past history of bipolar disorder, schizophrenia, or schizoaffective disorder. 2. Current obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses 3. Active suicidal intention, as determined by clinical interview assessment tool (Sheehan-STS) and clinical examination 4. Active or recent (\<12 months) substance use disorder; excluding nicotine 5. Administration of NMDA-antagonists (e.g., ketamine) in previous 3 months 6. Ongoing treatment with ECT 7. Presence of acute medical illness that could interfere with study participation, including significant pulmonary disease 8. Pregnancy or breastfeeding 9. Any contraindications to the use of nitrous

Related Trials